Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178751 | 0.83 | CYP2A6 (0.45) | ALDH1A1MAPTMMEECE1MRGPRX4 | |
| SCHEMBL24838713 | 0.83 | CYP2A6 (0.45) | ALDH1A1MAPTMMEECE1MRGPRX4 | |
| SCHEMBL550471 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTPGK1MMEECE1 | |
| SCHEMBL391198 | 0.79 | CA3 (0.42) | MAPK1MAPTPGK1MMEECE1 | |
| SCHEMBL26367663 | 0.77 | CYP3A4 (0.39) | TSHRACHE | |
| SCHEMBL187954 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTPGK1 | |
| SCHEMBL6117610 | 0.73 | — | — | |
| SCHEMBL392605 | 0.72 | PTGDR2 (0.39) | — | |
| SCHEMBL21201386 | 0.71 | ACHE (0.35) | TSHRMAPK1MAPTPTGS2ACHE | |
| SCHEMBL304892 | 0.71 | TSHR (0.48) | TSHRHSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TSHR 4388/4885MAPK1 4704/4885HSP90AB1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.